dlc1在骨髓增生异常综合征中的表达及临床意义探讨word格式论文.docxVIP

DLC-1在骨髓增生异常综合征中的表达及临床意义探讨摘要研究目的检测肝癌缺失因子-1（deleted in liver cancer-1,DLC-1）在骨髓增生异常综合征(myelodysplasticsyndrome，MDS)患者中的表达，探讨DLC-1基因在MDS中的临床意义。方法收集确诊为MDS患者30例，年龄25～79岁，中位年龄56岁。其中难治性贫血(RA)8例，难治性血细胞减少伴有多系发育异常(RCMD)4 例，难治性贫血伴原始细胞增多(RAEB-1)4例，难治性贫血伴原始细胞增多(RAEB-2)14 例。对照组10例，包括异基因造血干细胞移植供者5例，单纯白细胞减少5例。根据IPSS积分标准及危度划分进行分组，分为高、中、低危三组，采用实时荧光定量PCR检测DLC-1基因在MDS患者及对照组中的表达水平。结果30例MDS患者和10例对照均表达DLC-1，其中MDS患者DLC-1基因△Ct值为20.11±3.80，与对照组DLC-1基因△Ct值10.23±2.40比较有显著性差异(P0.05)，表明MDS患者DLC-1表达水平明显低于对照组（△Ct值越高DLC-1表达水平越低）。低危组MDS患者DLC-1基因△Ct值15.29±2.58中危组18.61±1.01高危组23.17±1.97，三组两两比较有显著性差异(P0.05)，表明低危组DLC-1 表达水平中危组高危组。RA、RCMD、RAEB-1、RAEB-2四组间DLC-1基因△Ct值差别无统计学意义(P0.05)。结论1DLC-1基因在MDS患者中呈低表达，可能与MDS发病机制相关。2DLC-1基因的表达水平可能与MDS患者预后相关。关键词MDS；DLC-1基因；预后；发病机制StudyoftheexpressionoftheDLC-1inmyelodysplasticsyndromes anditsclinicalimplicationAbstractObjectiveTodetecttheexpressionofdeletedinlivercancer-1(DLC-1)inthepatientswithmyelodysplasticsyndrome(MDS)anditsclinicalimplication.MethodSampleswerecollectedfrompatientswithmyelodysplasticsyndromefromJanuarytoOctoberin2010,diagnosisaccordingtotheWHOclassification.Thirtypatientsandtencontrolswereinvestigated:agingfrom25to79,themedianis56yearsold,includingMDS-RCMD(4),MDS-RA(8),MDS-RAEB-1(4)andMDS-RAEB-2(14)inMDSgroup.MDSpatientsweredividedinto3groups(high-risk,intermediate-riskandlow-risk)accordingtoIPSSclassification.TherelativeexpressionlevelsofDLC-1weredetectedbyrealtimequantitativePCR andanalyzedbySPSS13.0.ResultDLC-1wasexpressedinall30patientsand10controls.The△CtinMDSwas20.11±3.80，significantlyhigherthanthatofcontrolgroup(10.23±2.40)(P0.05).Therewassignificantdifferenceinthethreegroups(p0.05):low-riskgroup(15.29±2.58),intermediate-riskgroup(18.61±1.01),high-riskgroup(23.17±1.97).Therewasnodifferenceinthefourgroups(RA、RCMD、RAEB-1、RAEB-2),P0.05.ConclusionTheDLC-1expressionlevelsweresignificantlylowerinMDSpatientsthanthatofcontrolgroup(P0.05).Theexpression ofDLC-1genemay correlatewiththeprognosisofMDS.KeywordsMDS；DLC-1；prognosis；parthenogenesis主要缩略词表